GLP-1 Dosing Mistakes Are Sending Thousands of Calls to Poison Control

What the Researchers Found

Researchers at the University of Texas at San Antonio pulled national poison control center data spanning the years before and after semaglutide's 2021 approval for weight management, and the trend line is steep. Before 2021, GLP-1 receptor agonists were tied to roughly 1,000 to 1,500 calls a year nationwide. By 2023, that number had climbed past 8,000. The study, published in the Journal of Medical Toxicology and featured as a cover story in Significance, the flagship magazine of the Royal Statistical Society and American Statistical Association, is one of the clearer looks yet at what is actually driving those calls.

The answer is not what a lot of people would guess. Ninety-one percent of the cases were therapeutic errors: honest mistakes in how the medication was measured or taken, not intentional misuse. This is not a story about people abusing a drug. It is a story about a dosing schedule that is easier to get wrong than most people realize, catching careful, well-intentioned patients.

The Two Mistakes Behind Most of the Calls

Two patterns account for most of the therapeutic errors researchers identified.

A related pattern shows up in the broader poison-control literature on GLP-1s, though it is not part of this specific study: missing a weekly dose and then taking two doses close together to "catch up," which stacks side effects the schedule was never designed to deliver at once.

One Caveat Worth Being Precise About

This research looked at pharmaceutical Ozempic and Wegovy pens, which come with a fixed click-counter dose built in. It did not study compounded or research-grade peptide vials. That distinction matters, and it is worth being upfront about it rather than blurring the line.

What the study does establish is a failure mode: the schedule and the math around a GLP-1 medication are easier to get wrong than most people assume, even with a pen designed to guard against it. That failure mode does not disappear when the dose comes from a vial instead of a pen. If anything, a vial and a syringe remove the one safeguard a pen provides. There is no click-counter to catch a daily-instead-of-weekly mixup, and no built-in stop at a preset dose. Anyone measuring their own dose from a multi-dose vial is doing, by hand, exactly the math this study found so many pen users getting wrong.

Why This Is Worth Slowing Down For

None of this is a reason to panic. It is a reason to treat vial math the way this study suggests most people don't: as a step that deserves the same care as the substance itself. Before drawing up a dose, know the concentration in the vial, the volume that equals your intended dose, and the schedule you are following, and write it down somewhere you will actually check it. If a titration schedule is part of the plan, follow it in order rather than starting at the "end" dose because it seems more efficient.

What This Is, and Isn't

This is a report on a peer-reviewed study of poison control trends tied to FDA-approved GLP-1 medications, and a plain-language bridge to what it means for anyone measuring a dose from a research-grade vial. It is not medical advice, and it is not a suggestion that any specific dosing error is likely or inevitable. The study's own framing is that most of these cases were preventable with better patient education, which is exactly what careful, unhurried vial math is meant to provide.